Chapter 13. Chemotherapy of Advanced Colorectal Cancer

  1. John H. Scholefield1,
  2. Axel Grothey2,
  3. Herand Abcarian3 and
  4. Tim Maughan4
  1. Axel Grothey

Published Online: 14 JAN 2008

DOI: 10.1002/9780470753231.ch13

Challenges in Colorectal Cancer

Challenges in Colorectal Cancer

How to Cite

Grothey, A. (2006) Chemotherapy of Advanced Colorectal Cancer, in Challenges in Colorectal Cancer (eds J. H. Scholefield, A. Grothey, H. Abcarian and T. Maughan), Blackwell Publishing Ltd, Malden, Massachusetts, USA. doi: 10.1002/9780470753231.ch13

Editor Information

  1. 1

    Professor of Surgery, University Hospital, Nottingham, UK

  2. 2

    Professor, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

  3. 3

    Turi Josefsen Professor and Chairman, Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA

  4. 4

    Professor of Cancer Studies, University of Cardiff, Cardiff, UK

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2006

ISBN Information

Print ISBN: 9781405127066

Online ISBN: 9780470753231



  • chemotherapy;
  • colorectal cancer;
  • biomodulation;
  • tumor;
  • drugs


This chapter contains section titled:

  • What is the best sequence of chemotherapy options?

  • Can oral 5-FU prodrugs serve as substitute for infusional 5-FU in modern combination regimens?

  • Should a biologic agent be added upfront?

  • How long should first-line treatment be continued?

  • Can patients with metastatic disease be candidates for a curative approach?

  • Summary and conclusion